First Line Treatment of Metastatic Hormone Refractory Prostate Cancer With a Combination of Novantrone-Navelbine
- Determine the efficacy of the combination of mitoxantrone and vinorelbine in terms of
response rate, progression free survival, overall survival, and quality of life in
patients with metastatic hormone refractory adenocarcinoma of the prostate.
- Determine the toxicities of this treatment regimen in these patients.
OUTLINE: This is a multicenter study.
Patients receive vinorelbine IV on days 1 and 8 and mitoxantrone IV on day 8. Treatment
repeats every 3 weeks for up to 9 courses in the absence of disease progression or
Quality of life is assessed prior to treatment, prior to each course, and then at 2 months
after study completion.
Patients are followed every 3 months until disease progression.
PROJECTED ACCRUAL: A total of 14-39 patients will be accrued for this study.
Primary Purpose: Treatment
Jean-Louis Wendling, MD
Centre Hospitalier Intercommunal Toulon - La Seyne Sur Mer
United States: Federal Government